Octagon Capital Advisors LP Invests $5.15 Million in Maze Therapeutics, Inc. $MAZE

Key Points

• Octagon Capital Advisors LP has acquired a new stake in Maze Therapeutics by purchasing 468,000 shares valued at approximately $5.15 million, representing about 1.07% ownership of the company.
• Maze Therapeutics reported an earnings per share (EPS) of ($0.77) for the quarter, slightly surpassing the consensus estimate of ($0.79).
• According to analyst ratings, Maze Therapeutics has a consensus rating of "Buy" with a price target ranging from $17.00 to $34.00 set by various brokerages.

Octagon Capital Advisors LP acquired a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 468,000 shares of the company's stock, valued at approximately $5,153,000. Octagon Capital Advisors LP owned 1.07% of Maze Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $25,000. Corebridge Financial Inc. bought a new stake in Maze Therapeutics during the 1st quarter valued at approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Maze Therapeutics during the 1st quarter valued at approximately $57,000. Deutsche Bank AG purchased a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $98,000. Finally, Nuveen LLC bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $125,000.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MAZE shares. HC Wainwright lifted their price target on Maze Therapeutics from $34.00 to $50.00 and gave the company a "buy" rating in a research report on Friday. BTIG Research boosted their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a report on Friday. Wedbush began coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target for the company. Finally, Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $30.17.

Maze Therapeutics Stock Down 6.0%

NASDAQ:MAZE traded down $1.50 during trading hours on Friday, reaching $23.30. 1,266,987 shares of the company traded hands, compared to its average volume of 654,707. The business's 50-day moving average price is $15.28 and its two-hundred day moving average price is $12.28. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.